Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ACIU
#3419
AC Immune SA - Common Stock
2.6
5
USD
-0.02%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-2.21%
Monthly Change
+15.22%
6 month change
-6.36%
Year Change
+27.40%
Previous Close
2.7
1
Open
2.6
5
Low
2.6
5
High
2.6
5
Volume
5
Markets
US Stock Market
Healthcare
Biotechnology
ACIU
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
71.94 M
83.48 M
83.62 M
99.2 M
100.41 M
101.74 M
101.74 M
Valuation ratios
Enterprise value
371.91 M
413.22 M
184.8 M
465.24 M
271.11 M
319.47 M
282.84 M
Price to earnings ratio
—
—
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
—
—
Price to book ratio
—
—
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
—
—
—
Return on equity %
—
—
—
—
—
—
—
Return on invested capital %
—
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
—
—
—
—
—
—
—
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
—
—
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
—
—
Working capital per share
—
—
—
—
—
—
—
Book value per share
—
—
—
—
—
—
—
News
Here's Why You Should Add ARQT Stock to Your Portfolio Now
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
Here's Why You Should Add ACET Stock to Your Portfolio Now
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome